These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7540404)

  • 21. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW; Fuchs HA
    J Rheumatol; 1994 Apr; 21(4):752-3. PubMed ID: 8035405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR
    Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy using lymphokine-activated killer cells.
    Fowler JE
    J Urol; 1988 Jan; 139(1):148-9. PubMed ID: 3257273
    [No Abstract]   [Full Text] [Related]  

  • 25. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 26. [Properties of LAK cell activity and LAK-generation in PBL isolated from patients with renal cell carcinoma].
    Hayakawa M; Hatano T; Koyama Y; Masuda T; Higa I; Osawa A
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1497-503. PubMed ID: 3266646
    [No Abstract]   [Full Text] [Related]  

  • 27. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D
    Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 29. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies.
    West WH
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():83-9. PubMed ID: 2788509
    [No Abstract]   [Full Text] [Related]  

  • 30. New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer.
    Oliver RT
    Eur J Cancer; 1991; 27(9):1168-72. PubMed ID: 1835631
    [No Abstract]   [Full Text] [Related]  

  • 31. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
    Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
    Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical treatment of advanced renal cell carcinoma: present options and future directions.
    Canobbio L; Miglietta L; Boccardo F
    Cancer Treat Rev; 1996 Mar; 22(2):85-104. PubMed ID: 8665566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
    Robertson CN; Linehan WM; Pass HI; Gomella LG; Haas GP; Berman A; Merino M; Rosenberg SA
    J Urol; 1990 Sep; 144(3):614-7; discussion 617-8. PubMed ID: 2201792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2 in the treatment of renal cancer.
    Margolin KA
    Semin Oncol; 2000 Apr; 27(2):194-203. PubMed ID: 10768598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.